Adriana C. H. Neven

Adriana C. H. Neven

Auto-generated profile, based on publicly available information

Adriana C. H. Neven

Monash Health and Monash University 1 , Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
ANAdriana C H Neven
Adriana C H Neven
MFMaria Forslund
Maria Forslund
SRSanjeeva Ranashinha
Sanjeeva Ranashinha
Aya MousaAya Mousa
Aya Mousa
CTChau Thien Tay
Chau Thien Tay
JBJacqueline A. Boyle
Jacqueline A. Boyle
Objectives: To examine the global prevalence of polycystic ovary syndrome (PCOS) among adolescents across world regions, comparing the 2003 Rotterdam consensus criteria with the current International Evidence-based PCOS Guideline criteria which omits polycystic ovarian morphology (PCOM). Design: Systematic review and meta-analysis, Prospero CRD42022372029. Methods: OVID MEDLINE, All EBM, PsycInfo, EMBASE, and CINAHL were searched from 1990 to November 2023 for studies assessing the prevalence of PCOS in unselected adolescent populations. Results: Overall, 15 708 articles were identified. After removal of duplicates, 11 868 titles and abstracts and 445 full texts were assessed. Of these, 24 articles reporting on 23 studies from five world regions were included. In meta-analysis of 20 studies (n = 14 010 adolescents), global prevalence was 9.8% (95% CI 7.2, 12.3) according to original Rotterdam criteria, and 6.3% (95% CI 3.9, 8.8) according to International Evidence-based Guideline criteria. Global PCOS prevalence based on self-report was 9.8% (95% CI 5.5, 14.1). Grouped by WHO region, prevalence ranged from 2.9% (95% CI 2.0, 3.9) in the Western Pacific region to 11.4% (95% CI 7.1, 15.7) in the South-East Asia region according to guideline criteria. Conclusion: This paramount global meta-analysis on adolescent PCOS diagnosis directly informed the 2023 International PCOS Guideline. Guideline criteria generated a global PCOS prevalence of 6.3%, compared with 9.8% on Rotterdam criteria (including PCOM). Excluding PCOM, which overlaps with normal pubertal transition, is expected to deter over-diagnosis. To avoid under-diagnosis, the Guideline recommends identifying those with either irregular cycles or hyperandrogenism as being “at risk”; this group should undergo longitudinal serial evaluations until adulthood.

13 January 2026 in Human Reproduction Update
Verified
Journal Article
Closed access
ANAdriana C H Neven
Adriana C H Neven
MFMaria Forslund
Maria Forslund
SRSanjeeva Ranasinha
Sanjeeva Ranasinha
PSParneet Sethi
Parneet Sethi
RDRaja Ram Dhungana
Raja Ram Dhungana
JBJacqueline A. Boyle
Jacqueline A. Boyle
BACKGROUND: Polycystic ovary syndrome (PCOS) affects women globally, but its prevalence across World Health Organization (WHO) regions has not previously been reported. OBJECTIVE AND RATIONALE: We aimed to synthesize evidence on the prevalence of PCOS by diagnostic criteria and by WHO geographic regions to inform the International Evidence-Based PCOS Guideline. SEARCH METHODS: A systematic search of OVID MEDLINE, All EBM, PsycInfo, EMBASE, and Cumulative Index to Nursing and Allied Health Literature was conducted from 1990 to November 2024. Studies assessing PCOS prevalence in an unselected population were included. Non-primary studies or those with unclear diagnostic criteria were excluded. The primary outcome was PCOS prevalence among adult women. The secondary outcome was PCOS prevalence among women of all ages. Random effects meta-analysis using the DerSimonian and Laird method was applied for estimating the overall effect size. Two reviewers independently assessed risk-of-bias (RoB) and evidence certainty. OUTCOMES: The search yielded 16 664 articles, of which 119 unique studies (in 137 articles) were eligible, and 92 (including 157 181 participants) were pooled in a meta-analysis. By diagnostic criteria, PCOS global prevalence among adult women only was 12.1% (95% CI: 9.8, 14.8; I2: 98.8%) using Rotterdam criteria, 7.9% (95% CI: 6.2, 9.9; I2: 96.2%) using the original National Institute of Health (NIH) criteria, 12.7% (95% CI: 8.2, 17.9; I2: 98.0%) using the Androgen Excess (AE)-PCOS criteria, and 7.8% (95% CI: 5.8, 10.0; I2: 99.4%) by self-report. By WHO regions, PCOS prevalence among adult women when using Rotterdam criteria was highest in the Eastern Mediterranean region (15.1%; 95% CI: 11.1, 19.7) and the South-East Asian region (14.3%; 95% CI: 5.8, 25.9), followed by the European region (11.7%; 95% CI: 5.1, 20.3), the region of the Americas (10.5%; 95% CI: 3.0, 21.7), and the Western Pacific region (9.1%; 95% CI: 6.2, 12.5), with no data from Africa. Subgroup analysis using Cochran’s Q test indicated a statistically significant difference in prevalence by WHO region (P = 0.022). Subgroup analyses including adolescents yielded a lower prevalence globally, with a global prevalence of 11.4% (95% CI: 9.5, 13.5) by Rotterdam criteria, 7.1% (95% CI: 5.7, 8.7) by NIH criteria, 11.2% (95% CI: 7.4, 15.5) by AE-PCOS criteria, and 7.6% (95% CI: 5.8, 9.6) on self-report. Of the 119 studies, 30 had low, 49 had moderate, and 40 had high RoB. Certainty of evidence ranged from very low to low. WIDER IMPLICATIONS: This is the most comprehensive and contemporary review of PCOS prevalence and highlights past inconsistencies in diagnostic criteria and individual diagnostic features. Pooled PCOS prevalence was 12.1% by the Rotterdam criteria and was highest in the Eastern Mediterranean and the South-East Asian regions, with a potentially different health burden of PCOS across world regions. These findings directly inform International PCOS Guidelines, including updated guideline diagnostic criteria and refined individual features, emphasizing early, accurate diagnosis. REGISTRATION NUMBER: PROSPERO CRD42022372029.

8 September 2022 in Diabetic Medicine
Verified
Journal Article
Open access
ANAdriana C. H. Neven
Adriana C. H. Neven
ALAmelia Lake
Amelia Lake
AWAmelia Williams
Amelia Williams
SOSharleen O'reilly
Sharleen O'reilly
CHChristel Hendrieckx
Christel Hendrieckx
JBJacqueline A. Boyle
Jacqueline A. Boyle
Aims: Racial and ethnic disparities exist in gestational diabetes prevalence and risk of subsequent type 2 diabetes mellitus (T2DM). Postpartum engagement in healthy behaviours is recommended for prevention and early detection of T2DM, yet uptake is low among women from diverse cultural backgrounds. Greater understanding of factors impacting postpartum health behaviours is needed. Applying theTheoretical Domains Framework(TDF) andCapability,Opportunity,Motivation‐Behaviour(COM‐B) model, our aim was to synthesise barriers to and enablers of postpartum health behaviours among women from diverse cultural backgrounds with prior GDM and identify relevant intervention components.Methods: Databases, reference lists and grey literature were searched from September 2017 to April 2021. Two reviewers screened articles independently against inclusion criteria and extracted data. Using an inductive–deductive model, themes were mapped to the TDF and COM‐B model.Results: After screening 5148 citations and 139 full texts, we included 35 studies (N = 787 participants). The main ethnicities included Asian (43%), Indigenous (15%) and African (11%). Barriers and enablers focused onCapability(e.g. knowledge),Opportunity(e.g. competing demands, social support from family, friends and healthcare professionals, culturally appropriate education and resources) andMotivation(e.g. negative emotions, perceived consequences and necessity of health behaviours, social/cultural identity). Five relevant intervention functions are identified to link the barriers and enablers to evidence‐based recommendations for communications to support behaviour change.Conclusions: We provide a conceptual model to inform recommendations regarding the development of messaging and interventions to support women from diverse cultural backgrounds in engaging in healthy behaviours to reduce risk of T2DM.

25 December 2021 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
ALAmelia Lake
Amelia Lake
ANAdriana C. H. Neven
Adriana C. H. Neven
AWAmelia Williams
Amelia Williams
SOSharleen O'reilly
Sharleen O'reilly
CHChristel Hendrieckx
Christel Hendrieckx
TGthe ME‐MaGDA study group
the ME‐MaGDA study group

21 March 2024 in Human Reproduction
Verified
Journal Article
Open access
PDF file
HTHelena Jane Teede
Helena Jane Teede
ANA C H Neven
A C H Neven
APAlexia Sophie Peña
Alexia Sophie Peña
Polycystic ovarian syndrome (PCOS) is the most common endocrinopathy in reproductive age women and has significant clinical reproductive, cardiometabolic, dermatological and psychological features ( Teede et al., 2010). Diagnostic criteria have evolved historically, resulting in variable global prevalence estimates. The key historical criteria include the 1990 National Institute of Health (NIH) which requires both hyperandrogenism (HA) (clinical and/or biochemical) and ovulatory dysfunction (OD) for diagnosis, without defining these individual criteria ( Zawadski and Dunaif, 1992). The 2003 Rotterdam consensus criteria led by the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM), defined PCOS based on at least two out of three of HA, OD, and ultrasound characteristics of polycystic ovarian morphology (PCOM) after exclusion of other causes ( Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004).

16 September 2026 in Diabetes Care
Verified
Journal Article
Closed access
ANAdriana C.H. Neven
Adriana C.H. Neven
PSParneet Sethi
Parneet Sethi
WHWilliam M. Hague
William M. Hague
NCN. Wah Cheung
N. Wah Cheung
EHEmily Hibbert
Emily Hibbert
URUma Ram
Uma Ram
OBJECTIVE: To investigate associations between polyendocrine metabolic ovarian syndrome (PMOS) and maternal and neonatal outcomes and explore interactions with BMI and ethnicity. RESEARCH DESIGN AND METHODS: This was a prospective nested cohort study of pregnant women with risk factors for hyperglycemia enrolled in an international, multicenter, randomized controlled trial of gestational diabetes mellitus (GDM) treatment. We compared baseline and pregnancy characteristics, evaluated adverse maternal and neonatal outcomes by PMOS status, and used multivariable regression models to evaluate factors (maternal age, baseline BMI, ethnicity, parity, smoking, and level of education) that independently affected maternal and neonatal outcomes. RESULTS: Of 3,645 participants, PMOS prevalence was 17.1% (95% CI 15.9, 18.3). At booking visits, women with PMOS (vs. without) were younger (30.6 ± 4.7 vs. 31.3 ± 5.2 years; P < 0.001) and had higher median (interquartile range) BMI at baseline (29.8 [25.1–35.7] vs. 28.1 [24.1–33.9] kg/m2; P < 0.001), and more were primigravid (30.2% [n = 188] vs. 25.7% [n = 778]; P = 0.022). There were positive associations between PMOS and early GDM, with an adjusted odds ratio (aOR) of 1.37 (95% CI 1.10, 1.72), a composite of adverse neonatal outcomes (aOR 1.28 [95% CI 1.04, 1.58]), admission to a neonatal special care nursery or neonatal intensive care unit (aOR 1.32 [95% CI 1.05–1.65]), and negative associations between PMOS and gestational age at birth (−1.60 days [95% CI −2.82, −0.39]) and birth length (−0.33 cm [95% CI −0.61, −0.04]). No interactions were found with baseline BMI and ethnicity. CONCLUSIONS: PMOS was associated with higher odds of early GDM, and neonatal outcomes were poorer on adjusted analyses, highlighting independent pregnancy risks in PMOS and the need to identify, monitor, and treat women with PMOS to mitigate risks of adverse pregnancy outcomes.